Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05987124 · ClinicalTrials.gov registry record · Phase 2
Defibrotide Dose-escalation for SOS Post-HSCT
A Phase 2 study of Veno-occlusive Disease and Sinusoidal Obstruction Syndrome, sponsored by New York Medical College.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05987124: Recruiting Phase 2 study of Veno-occlusive Disease and Sinusoidal Obstruction Syndrome, sponsored by New York Medical College.
NCT05987124 is a Phase 2 study of Veno-occlusive Disease and Sinusoidal Obstruction Syndrome that is actively recruiting participants, run by New York Medical College. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05987124, a Phase 2 study of Veno-occlusive Disease and Sinusoidal Obstruction Syndrome, is actively recruiting participants, sponsored by New York Medical College.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is being done to determine the safety and tolerability of increasing doses of defibrotide within a single patient with sinusoidal obstructive syndrome (SOS)/veno-occlusive disease (VOD) after hematopoietic cell transplantation (HCT) associated with either kidney and/or lung impairment that has not obtained a complete response (CR) or progressed in severity with standard doses of defibrotide.
Primary Outcome
grade 3 and 4 adverse events possible or probably related to defibrotide will be collected
Conditions Studied
Interventions
- DRUG Defibrotide
Study Locations (1)
New York
- New York Medical College - Valhalla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-03-20 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 2 |
What NCT05987124 shows while recruiting
NCT05987124 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Veno-occlusive Disease appearing as the primary indexed condition, and to 1 intervention - of which Defibrotide is the first listed.
NCT05987124 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05987124 about?
NCT05987124 is a clinical study titled "Defibrotide Dose-escalation for SOS Post-HSCT". This research study is being done to determine the safety and tolerability of increasing doses of defibrotide within a single patient with sinusoidal obstructive syndrome (SOS)/veno-occlusive disease (VOD) after hematopoietic cell transplantation (HCT) associated with either kidney and/or lung impai...
What is the current status of trial NCT05987124?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-03-20. Estimated completion is 2027-08-01.
What conditions does trial NCT05987124 study?
This clinical trial studies the following conditions: Veno-occlusive Disease, Sinusoidal Obstruction Syndrome.
What interventions are being tested in trial NCT05987124?
The interventions under investigation include: Defibrotide (DRUG).
Who is sponsoring clinical trial NCT05987124?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05987124 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Veno-occlusive Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05987124's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI